Stacey Anne May, M.A. (Director of Public Outreach, American Association of Pharmaceutical Scientists)
Michael Levy, M.Sc., M.B.A. (Vice President & Head, USP Quality Institute and Head of Research and Innovation, USP)
Date: Tuesday, April 24
Time: 2:45pm - 3:30pm
Conference Pass, VIP Attendee -
Get your pass now!
Vault Recording: TBD
The very nature of medicines and the technologies used to develop, manufacture, deliver, and test them are continuously evolving. Ensuring that patients have access to quality-assured medicines requires that quality standards also evolve. While predominant, the paradigm of release testing small molecular weight medicines with traditional approaches (e.g., HPLC) will have to shift to account for ever more complex treatments (e.g., gene therapy), produced in new ways (e.g., pharmaceutical continuous manufacturing),assessed differently (e.g., Quantitative Nuclear Magnetic Resonance), and at different times (e.g., inline). This session will provide an overview of some of the work being done at USP to address these questions and ensure the availability of quality medicines.